S
SynAct Pharma AB
STO:SYNACT
SynAct Pharma AB
STO:SYNACT
Price:
17.42
SEK
-0.57%
Market Closed
Market Cap:
kr929m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Keyware Solutions Inc
TSE:3799
|
JP |
|
Vedanta Ltd
BSE:500295
|
IN |
|
I
|
Integrated Design & Engineering Holdings Co Ltd
TSE:9161
|
JP |
|
Hensoldt AG
XETRA:HAG
|
DE |
|
H
|
HiteJinro Holdings Co Ltd
KRX:000140
|
KR |
|
EnerSys
NYSE:ENS
|
US |
SynAct Pharma AB
Intangible Assets
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
SynAct Pharma AB
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SynAct Pharma AB
STO:SYNACT
|
Intangible Assets
kr147.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Intangible Assets
kr702k
|
CAGR 3-Years
-75%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Intangible Assets
kr14.9m
|
CAGR 3-Years
21%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Intangible Assets
kr3.8B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
67%
|
CAGR 10-Years
37%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Intangible Assets
kr40.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
25%
|
|
|
BioArctic AB
STO:BIOA B
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
No Stocks Found
SynAct Pharma AB
Glance View
SynAct Pharma AB engages in the development of pharmaceutical drugs for the treatment of inflammatory diseases. The company is headquartered in Lund, Skane. The company went IPO on 2016-07-11. The firm is located in Lund, Sweden. The company develops medicines for acute impairment in inflammatory diseases. The firm's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.
SYNACT Intrinsic Value
LOCKED
See Also
What is SynAct Pharma AB's Intangible Assets?
Intangible Assets
147.8m
SEK
147.8m
SEK
Based on the financial report for Dec 31, 2025, SynAct Pharma AB's Intangible Assets amounts to 147.8m SEK.
What is SynAct Pharma AB's Intangible Assets growth rate?
Intangible Assets CAGR 1Y
-4%
-4%
Over the last year, the Intangible Assets growth was -4%.
